Roche Launches $100M Cancer Immunotherapy R&D Network

The new Centers of Research Excellence (imCORE™) Network aims to advance promising new immuno-oncology treatments

Sanofi Assumes R&D Efforts for Warp Drive Aminoglycoside Antibiotics

The program is among several that Warp Drive Bio is pursuing as part of discovery efforts based on its novel Genome Mining™ technology platform

Fate Therapeutics Wins $4M Grant to Advance NK Cancer Immunotherapy

CIRM grant aims to support first-in-human trial for FT516, off-the-shelf engineered natural killer cell therapy in combination therapy for breast cancer

AMRI Wins Five-Year $43M NIH Contract for Work Focused on CNS...

Initial $10 million funding will target development of at least one Phase I candidate.

CRISPR-Cas Technique Reverses Antibiotic Resistance in Bacteria

Scientists at Tel Aviv University say they have developed a tool that tackles the problem of antibiotic resistance.

ZMC Nabs Chinese Rights to TaiGen’s Late-Stage Antibiotic for $8M

Nemonaxacin is in development initially for treating CAP and diabetic foot ulcers.

Sartorius Stedim Biotech Acquires BioOutsource

Sartorius Stedim Biotech (SSB) acquired Glasgow-based BioOutsource, which provides contract testing services.

Circulating Cancer Cells Torpedoed by Peptide–Chemo Conjugate

Metastasis in a mouse model of breast cancer inhibited by a peptide–drug conjugate that targets circulating cancer cells

Orchard Therapeutics to Build Out Gene Therapy Manufacturing Site in Fremont,...

Orchard Therapeutics said it will build out a gene therapy manufacturing facility in Fremont, CA, that will employ 100 people and increase its manufacturing...

Millennium Gains Seattle’s Late-Stage Lymphoma Drug with Initial $60M Fee

Seattle Genetics retains commercialization rights in the U.S. and Canada. Takeda Pharmaceutical has exclusive commercialization rights in the rest of the world.

Recently Featured

Stay Connected

557,655FansLike
45,799FollowersFollow
Scroll Up